The Bioequivalence of Abexinostat (CRA‐024781) Tosylate Tablets (20 mg) in Chinese Healthy Subjects Under Fasting Conditions
This study aimed to investigate the pharmacokinetic parameters of single oral administration of postchange and prechange abexinostat (CRA‐024781) tosylate tablets in Chinese healthy subjects under fasting conditions, and assess the bioequivalence (BE) of the 2 formulations (Test [T1] and Reference [...
Saved in:
| Published in | Clinical pharmacology in drug development Vol. 13; no. 9; pp. 1061 - 1070 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
Oxford
Wiley Subscription Services, Inc
01.09.2024
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | This study aimed to investigate the pharmacokinetic parameters of single oral administration of postchange and prechange abexinostat (CRA‐024781) tosylate tablets in Chinese healthy subjects under fasting conditions, and assess the bioequivalence (BE) of the 2 formulations (Test [T1] and Reference [T2]). This study was a randomized, open‐label, 2‐formulation, fasting administration, single‐dose, 2‐sequence, 2‐cycle, crossover BE study. Thirty‐six subjects were enrolled in the study and 33 subjects completed 2 cycles. The plasma concentrations were determined by liquid chromatography‐tandem mass spectrometry. The 90% confidence intervals (CIs) for the Cmax, AUC0‐t, and AUC0‐∞ of CRA‐024781 and its 2 major metabolites (PCI‐27789 and PCI‐27887, both metabolites are pharmacologically inactive on HDAC1) fell within the acceptable range of 80%‐125%. The results suggest that the CRA‐024781 test preparation (Test [T1]) is bioequivalent to the reference preparation (Reference [T2]) in healthy Chinese subjects under fasting conditions. |
|---|---|
| AbstractList | This study aimed to investigate the pharmacokinetic parameters of single oral administration of postchange and prechange abexinostat (CRA‐024781) tosylate tablets in Chinese healthy subjects under fasting conditions, and assess the bioequivalence (BE) of the 2 formulations (Test [T1] and Reference [T2]). This study was a randomized, open‐label, 2‐formulation, fasting administration, single‐dose, 2‐sequence, 2‐cycle, crossover BE study. Thirty‐six subjects were enrolled in the study and 33 subjects completed 2 cycles. The plasma concentrations were determined by liquid chromatography‐tandem mass spectrometry. The 90% confidence intervals (CIs) for the C
max
, AUC
0‐t
, and AUC
0‐∞
of CRA‐024781 and its 2 major metabolites (PCI‐27789 and PCI‐27887, both metabolites are pharmacologically inactive on HDAC1) fell within the acceptable range of 80%‐125%. The results suggest that the CRA‐024781 test preparation (Test [T1]) is bioequivalent to the reference preparation (Reference [T2]) in healthy Chinese subjects under fasting conditions. This study aimed to investigate the pharmacokinetic parameters of single oral administration of postchange and prechange abexinostat (CRA‐024781) tosylate tablets in Chinese healthy subjects under fasting conditions, and assess the bioequivalence (BE) of the 2 formulations (Test [T1] and Reference [T2]). This study was a randomized, open‐label, 2‐formulation, fasting administration, single‐dose, 2‐sequence, 2‐cycle, crossover BE study. Thirty‐six subjects were enrolled in the study and 33 subjects completed 2 cycles. The plasma concentrations were determined by liquid chromatography‐tandem mass spectrometry. The 90% confidence intervals (CIs) for the Cmax, AUC0‐t, and AUC0‐∞ of CRA‐024781 and its 2 major metabolites (PCI‐27789 and PCI‐27887, both metabolites are pharmacologically inactive on HDAC1) fell within the acceptable range of 80%‐125%. The results suggest that the CRA‐024781 test preparation (Test [T1]) is bioequivalent to the reference preparation (Reference [T2]) in healthy Chinese subjects under fasting conditions. This study aimed to investigate the pharmacokinetic parameters of single oral administration of postchange and prechange abexinostat (CRA-024781) tosylate tablets in Chinese healthy subjects under fasting conditions, and assess the bioequivalence (BE) of the 2 formulations (Test [T1] and Reference [T2]). This study was a randomized, open-label, 2-formulation, fasting administration, single-dose, 2-sequence, 2-cycle, crossover BE study. Thirty-six subjects were enrolled in the study and 33 subjects completed 2 cycles. The plasma concentrations were determined by liquid chromatography-tandem mass spectrometry. The 90% confidence intervals (CIs) for the Cmax, AUC0-t, and AUC0-∞ of CRA-024781 and its 2 major metabolites (PCI-27789 and PCI-27887, both metabolites are pharmacologically inactive on HDAC1) fell within the acceptable range of 80%-125%. The results suggest that the CRA-024781 test preparation (Test [T1]) is bioequivalent to the reference preparation (Reference [T2]) in healthy Chinese subjects under fasting conditions.This study aimed to investigate the pharmacokinetic parameters of single oral administration of postchange and prechange abexinostat (CRA-024781) tosylate tablets in Chinese healthy subjects under fasting conditions, and assess the bioequivalence (BE) of the 2 formulations (Test [T1] and Reference [T2]). This study was a randomized, open-label, 2-formulation, fasting administration, single-dose, 2-sequence, 2-cycle, crossover BE study. Thirty-six subjects were enrolled in the study and 33 subjects completed 2 cycles. The plasma concentrations were determined by liquid chromatography-tandem mass spectrometry. The 90% confidence intervals (CIs) for the Cmax, AUC0-t, and AUC0-∞ of CRA-024781 and its 2 major metabolites (PCI-27789 and PCI-27887, both metabolites are pharmacologically inactive on HDAC1) fell within the acceptable range of 80%-125%. The results suggest that the CRA-024781 test preparation (Test [T1]) is bioequivalent to the reference preparation (Reference [T2]) in healthy Chinese subjects under fasting conditions. |
| Author | Tan, Gewen Li, Xiang Chen, Jian Guo, Wenqiang |
| Author_xml | – sequence: 1 givenname: Xiang surname: Li fullname: Li, Xiang organization: Tianjin Cancer Institute of lntegrative Traditional Chinese and Western Medicine – sequence: 2 givenname: Wenqiang surname: Guo fullname: Guo, Wenqiang organization: Xynomic Pharmaceuticals (Nanjing) Co., Ltd – sequence: 3 givenname: Jian surname: Chen fullname: Chen, Jian organization: Hangzhou Normal University – sequence: 4 givenname: Gewen surname: Tan fullname: Tan, Gewen email: gewen.tan@xynomicpharma.com organization: Xynomic Pharmaceuticals (Nanjing) Co., Ltd |
| BookMark | eNp10c1OGzEQB3CrAomUcuANLPWSHAJjez-8x3TTABJSEQ1Sbyt7PUscbexkvUvJCR6hj9Bn4VH6JN2QigNSfRkffjMazf8jOXDeISGnDM4YAD8v18acsSiSH8iAswTGaRLJg7e_-HFETkJYQv8SYIxFA_I0XyD9Yj1uOvuganQlUl_RicZH63xoVUuH-e3kz_Mv4FEq2YjOfdjWqkU6V7rGNtAhh5ffq_sRtY7mC-swIL1EVbeLLf3e6SWWPbpzBhs6U6G17p7m3hnbWu_CJ3JYqTrgyb96TO5mX-f55fj628VVPrkelxxiOeaQpUbrimWpLmWmRcal0YaVQqdoKpZwyTjojHFVcaPjFAyqFCKVxSKNOYhjMtzPXTd-02Foi5UNJda1cui7UAiQXDCQSdzTz-_o0neN67frVZYJwfur9mq0V2XjQ2iwKtaNXalmWzAodmkUuzSKXRq9Pd_bn7bG7f9hkd9Mp68dfwHsRozy |
| Cites_doi | 10.1007/s00280-010-1344-7 10.1158/1078-0432.CCR-08-2787 10.1158/1535-7163.MCT-05-0442 10.1021/acs.jmedchem.7b00969 10.1038/nrc1779 10.1158/1078-0432.CCR-08-2714 10.1016/j.hoc.2012.01.006 10.1016/j.jprot.2015.12.018 10.2217/pgs-2016-0113 10.1080/10428194.2016.1263843 10.1155/2010/207420 10.1007/s10637-014-0118-1 10.18632/oncotarget.14147 10.1007/s11095-013-1089-1 10.7150/ijbs.9067 10.1186/s13148-015-0157-2 10.1186/gm323 10.1158/1078-0432.CCR-15-0624 10.1200/JCO.2016.70.5350 10.4155/fmc.12.3 10.3324/haematol.2016.154377 10.1038/nrd2133 10.1002/cncr.29175 10.1038/35106079 |
| ContentType | Journal Article |
| Copyright | 2024, The American College of Clinical Pharmacology. American College of Clinical Pharmacology. |
| Copyright_xml | – notice: 2024, The American College of Clinical Pharmacology. – notice: American College of Clinical Pharmacology. |
| DBID | AAYXX CITATION K9. 7X8 |
| DOI | 10.1002/cpdd.1448 |
| DatabaseName | CrossRef ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitle | CrossRef ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE - Academic ProQuest Health & Medical Complete (Alumni) |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 2160-7648 |
| EndPage | 1070 |
| ExternalDocumentID | 10_1002_cpdd_1448 CPDD1448 |
| Genre | article |
| GroupedDBID | -MK 05W 0R~ 1OC 33P 3SF 52U 52V 53G 8-1 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAONW AAXRX AAYCA AAZKR ABCUV ABDBF ABJNI ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACRPL ACUHS ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUYR AFBPY AFFPM AFGKR AFPWT AFWVQ AHBTC AIACR AITYG AIURR AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZFZN AZVAB BDRZF BFHJK BHBCM BMXJE BNHUX BOGZA BRXPI C45 DCZOG DPXWK DRFUL DRMAN DRSTM EBS EJD FUBAC G-S GODZA H13 HGLYW KBYEO LATKE LEEKS LH4 LITHE LOXES LSO LUTES LW6 LYRES MEWTI MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM MY~ O66 O9- OVD P2W PQQKQ R.K ROL SUPJJ TEORI TUS WBKPD WIH WIJ WIK WOHZO WOIKV WPGGZ WXSBR WYJ ZZTAW AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY K9. 7X8 |
| ID | FETCH-LOGICAL-c2058-2097dbbf197bc89b3928dbd1c3b7edf1628120b912af2db570dea704a95375203 |
| ISSN | 2160-763X 2160-7648 |
| IngestDate | Fri Jul 11 10:43:21 EDT 2025 Sat Jul 26 02:12:31 EDT 2025 Tue Jul 01 00:19:16 EDT 2025 Wed Jan 22 17:14:43 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c2058-2097dbbf197bc89b3928dbd1c3b7edf1628120b912af2db570dea704a95375203 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 |
| PQID | 3099332648 |
| PQPubID | 2034576 |
| PageCount | 10 |
| ParticipantIDs | proquest_miscellaneous_3082310865 proquest_journals_3099332648 crossref_primary_10_1002_cpdd_1448 wiley_primary_10_1002_cpdd_1448_CPDD1448 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | September 2024 2024-09-00 20240901 |
| PublicationDateYYYYMMDD | 2024-09-01 |
| PublicationDate_xml | – month: 09 year: 2024 text: September 2024 |
| PublicationDecade | 2020 |
| PublicationPlace | Oxford |
| PublicationPlace_xml | – name: Oxford |
| PublicationTitle | Clinical pharmacology in drug development |
| PublicationYear | 2024 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | 2010; 2010 2017; 58 2017; 35 2013; 30 2015; 121 2011; 31 2006; 5 2016; 133 2006; 6 2011; 67 2001; 1 2018; 61 2012; 26 2016; 17 2012; 4 2017; 102 2015; 7 2016; 8 2009; 15 2014; 10 2014; 32 2016; 22 e_1_2_10_23_1 e_1_2_10_24_1 e_1_2_10_21_1 e_1_2_10_22_1 e_1_2_10_20_1 e_1_2_10_2_1 e_1_2_10_4_1 e_1_2_10_18_1 e_1_2_10_3_1 e_1_2_10_19_1 e_1_2_10_6_1 e_1_2_10_5_1 e_1_2_10_17_1 e_1_2_10_8_1 e_1_2_10_14_1 e_1_2_10_7_1 e_1_2_10_15_1 e_1_2_10_12_1 e_1_2_10_9_1 e_1_2_10_13_1 e_1_2_10_10_1 e_1_2_10_11_1 Yang C (e_1_2_10_16_1) 2011; 31 e_1_2_10_27_1 e_1_2_10_25_1 e_1_2_10_26_1 |
| References_xml | – volume: 58 start-page: 1880 issue: 8 year: 2017 end-page: 1886 article-title: Phase 1 dose‐escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher‐risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia publication-title: Leuk Lymphoma – volume: 15 start-page: 3947 issue: 12 year: 2009 end-page: 3957 article-title: Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications publication-title: Clin Cancer Res – volume: 26 start-page: 671 issue: 3 year: 2012 end-page: 704 article-title: Role of histone deacetylase inhibitors in the treatment of lymphomas and multiple myeloma publication-title: Hematol Oncol Clin North Am – volume: 102 start-page: 903 issue: 5 year: 2017 end-page: 909 article-title: Safety and efficacy of abexinostat, a pan‐histone deacetylase inhibitor, in non‐Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study publication-title: Haematologica – volume: 32 start-page: 985 issue: 5 year: 2014 end-page: 994 article-title: Pharmacokinetic/pharmacodynamic modeling of abexinostat‐induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients publication-title: Invest New Drugs – volume: 6 start-page: 38 issue: 1 year: 2006 end-page: 51 article-title: Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer publication-title: Nat Rev Cancer – volume: 22 start-page: 1059 year: 2016 end-page: 1066 article-title: A phase I/II multicenter, open‐label study of the oral histone deacetylase inhibitor abexinostat in relapsed/refractory lymphoma publication-title: Clin Cancer Res – volume: 17 start-page: 1807 issue: 16 year: 2016 end-page: 1815 article-title: Pharmacogenomics and histone deacetylase inhibitors publication-title: Pharmacogenomics – volume: 61 start-page: 4273 issue: 10 year: 2018 end-page: 4282 article-title: Relevance of half‐life in drug design publication-title: J Med Chem – volume: 30 start-page: 2640 issue: 10 year: 2013 end-page: 2653 article-title: Application of hematological toxicity modeling in clinical development of abexinostat (S‐78454, PCI‐24781), a new histone deacetylase inhibitor publication-title: Pharm Res – volume: 1 start-page: 194 issue: 3 year: 2001 end-page: 202 article-title: Histone deacetylases and cancer: causes and therapies publication-title: Nat Rev Cancer – volume: 8 start-page: 56199 issue: 34 year: 2016 end-page: 56209 article-title: A phase 1 dose‐escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors publication-title: Oncotarget – volume: 4 start-page: 505 issue: 4 year: 2012 end-page: 524 article-title: Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed [published correction appears in Future Med Chem. 2012 Jun;4(10):1369‐70] publication-title: Future Med Chem – volume: 31 start-page: 1115 issue: 4 year: 2011 end-page: 1123 article-title: Histone deacetylase inhibitor PCI‐24781 enhances chemotherapy‐induced apoptosis in multidrug‐resistant sarcoma cell lines publication-title: Anticancer Res – volume: 7 start-page: 127 year: 2015 article-title: Epigenetic treatment of solid tumours: a review of clinical trials publication-title: Clin Epigenetics – volume: 35 start-page: 1231 issue: 11 year: 2017 end-page: 1239 article-title: Inhibiting histone deacetylase as a means to reverse resistance to angiogenesis inhibitors: phase I study of Abexinostat plus pazopanib in advanced solid tumor malignancies publication-title: J Clin Oncol – volume: 10 start-page: 757 issue: 7 year: 2014 end-page: 770 article-title: Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications publication-title: Int J Biol Sci – volume: 4 start-page: 24 issue: 3 year: 2012 article-title: Epigenetic variability in cells of normal cytology is associated with the risk of future morphological transformation publication-title: Genome Med – volume: 67 start-page: 439 issue: 2 year: 2011 end-page: 446 article-title: Histone deacetylase inhibitor (HDACI) PCI‐24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells publication-title: Cancer Chemother Pharmacol – volume: 5 start-page: 769 issue: 9 year: 2006 end-page: 784 article-title: Anticancer activities of histone deacetylase inhibitors publication-title: Nat Rev Drug Discov – volume: 5 start-page: 1309 issue: 5 year: 2006 end-page: 1317 article-title: CRA‐024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo publication-title: Mol Cancer Ther – volume: 121 start-page: 1223 issue: 8 year: 2015 end-page: 1230 article-title: Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma publication-title: Cancer – volume: 133 start-page: 125 year: 2016 end-page: 133 article-title: HDAC inhibitors induce global changes in histone lysine and arginine methylation and alter expression of lysine demethylases publication-title: J Proteomics – volume: 15 start-page: 3472 issue: 10 year: 2009 end-page: 3483 article-title: Combining PCI‐24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma publication-title: Clin Cancer Res – volume: 2010 year: 2010 article-title: PCI‐24781, a novel hydroxamic acid HDAC inhibitor, exerts cytotoxicity and histone alterations via caspase‐8 and FADD in leukemia cells publication-title: Int J Cell Biol – volume: 22 start-page: 1059 issue: 5 year: 2016 end-page: 1066 article-title: A phase I/II multicenter, open‐label study of the oral histone deacetylase inhibitor abexinostat in relapsed/refractory lymphoma publication-title: Clin Cancer Res – ident: e_1_2_10_15_1 doi: 10.1007/s00280-010-1344-7 – ident: e_1_2_10_8_1 doi: 10.1158/1078-0432.CCR-08-2787 – ident: e_1_2_10_13_1 doi: 10.1158/1535-7163.MCT-05-0442 – ident: e_1_2_10_19_1 doi: 10.1021/acs.jmedchem.7b00969 – ident: e_1_2_10_4_1 doi: 10.1038/nrc1779 – ident: e_1_2_10_12_1 doi: 10.1158/1078-0432.CCR-08-2714 – ident: e_1_2_10_11_1 doi: 10.1016/j.hoc.2012.01.006 – ident: e_1_2_10_5_1 doi: 10.1016/j.jprot.2015.12.018 – ident: e_1_2_10_23_1 doi: 10.2217/pgs-2016-0113 – ident: e_1_2_10_26_1 doi: 10.1080/10428194.2016.1263843 – ident: e_1_2_10_14_1 doi: 10.1155/2010/207420 – ident: e_1_2_10_21_1 doi: 10.1007/s10637-014-0118-1 – ident: e_1_2_10_24_1 doi: 10.18632/oncotarget.14147 – ident: e_1_2_10_20_1 doi: 10.1007/s11095-013-1089-1 – ident: e_1_2_10_10_1 doi: 10.7150/ijbs.9067 – ident: e_1_2_10_7_1 doi: 10.1186/s13148-015-0157-2 – ident: e_1_2_10_3_1 doi: 10.1186/gm323 – ident: e_1_2_10_22_1 doi: 10.1158/1078-0432.CCR-15-0624 – ident: e_1_2_10_25_1 doi: 10.1200/JCO.2016.70.5350 – ident: e_1_2_10_6_1 doi: 10.4155/fmc.12.3 – ident: e_1_2_10_18_1 doi: 10.3324/haematol.2016.154377 – ident: e_1_2_10_2_1 doi: 10.1038/nrd2133 – ident: e_1_2_10_27_1 doi: 10.1002/cncr.29175 – volume: 31 start-page: 1115 issue: 4 year: 2011 ident: e_1_2_10_16_1 article-title: Histone deacetylase inhibitor PCI‐24781 enhances chemotherapy‐induced apoptosis in multidrug‐resistant sarcoma cell lines publication-title: Anticancer Res – ident: e_1_2_10_9_1 doi: 10.1038/35106079 – ident: e_1_2_10_17_1 doi: 10.1158/1078-0432.CCR-15-0624 |
| SSID | ssj0000601114 |
| Score | 2.2901947 |
| Snippet | This study aimed to investigate the pharmacokinetic parameters of single oral administration of postchange and prechange abexinostat (CRA‐024781) tosylate... This study aimed to investigate the pharmacokinetic parameters of single oral administration of postchange and prechange abexinostat (CRA-024781) tosylate... |
| SourceID | proquest crossref wiley |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 1061 |
| SubjectTerms | abexinostat (CRA‐024781) bioequivalence healthy subjects histone deacetylase inhibitor (HDACi) pharmacokinetics |
| Title | The Bioequivalence of Abexinostat (CRA‐024781) Tosylate Tablets (20 mg) in Chinese Healthy Subjects Under Fasting Conditions |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcpdd.1448 https://www.proquest.com/docview/3099332648 https://www.proquest.com/docview/3082310865 |
| Volume | 13 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db9MwFLVK98ILGl-iMJBBaOrUZSRO0ySP_ViZUBkVSkXfIjt2SyeWdGsjGOKBn861YyeZVKTBSxTZrVP1HNv3Xt9zg9DbIBEB4U5iBWGXW7BfUysUC8_ijNsucRJGVd2Cj-e9s1n3w9ybNxq_a1lL-ZadJD936kr-B1VoA1ylSvYfkC0HhQa4B3zhCgjD9c4YD1aZuMpXMKyao9KwZOLHKs2kVEid0X7uW7BF-oEjIwBRtrn5BvZlJ5Kaqa2KuRK7c7mUnVIB-FW9k1LLk9TCcqESPtQLkjpjutkWmQLyqLuM9ZlSB0Zmua4KYitdIb_Ol0afVU-1mahcgjlQdFkmAuUqePtFpFf15qFRkdToHBXB2_fiu9az6egF6ZbpWXqRI07PtvxeUW3zROxoM6u0W2NjWFtypU-7cy8oassma87lCXZQbXjmkP_8UzyeTSZxdDqP7qE9Ao4GaaK9_mA0GJdxOlmvxlEl4sufZQpU2eRdOfpts6byVeoejzJZon30QPsauF8Q5yFqiPQROpwW2Nwc46jS3m2O8SGe1lB7jH5BN77NLpwtcI1duF1x6wgbZmHNLNwmNr5cHuFVijWrsGYVNqzCilVYswpXrHqCZuPTaHhm6Xd1WAmxPTktQ58ztnBCnyVByMDsDmC-O4nLfMEXTo-AJWmz0CF0QTjzfJsL6ttdGnqu7xHbfYqaaZaKZwhzv0cD-JJwXNYFC4uGQWInDLxAmgSCihZ6Y_7qeF2UZImL4tsklnjEEo8WOjAgxHrGbmIX3CHXlTmdLfS67Ib1VB6S0VRkufyMPBgHR99robYC7-8PiYfT0UjePL_DcC_Q_WoCHKDm9joXL8Gg3bJXmnN_ADmGoDc |
| linkProvider | EBSCOhost |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Bioequivalence+of+Abexinostat+%28CRA-024781%29+Tosylate+Tablets+%2820+mg%29+in+Chinese+Healthy+Subjects+Under+Fasting+Conditions&rft.jtitle=Clinical+pharmacology+in+drug+development&rft.au=Li%2C+Xiang&rft.au=Guo%2C+Wenqiang&rft.au=Chen%2C+Jian&rft.au=Tan%2C+Gewen&rft.date=2024-09-01&rft.issn=2160-7648&rft.eissn=2160-7648&rft.volume=13&rft.issue=9&rft.spage=1061&rft_id=info:doi/10.1002%2Fcpdd.1448&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2160-763X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2160-763X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2160-763X&client=summon |